+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Coronavirus Disease 2019 (COVID-19) Company Impact - Moderna Inc

  • PDF Icon

    Company Profile

  • 30 Pages
  • June 2020
  • GlobalData
  • ID: 5117334
Summary

This report gives an important expert analysis on how COVID-19 will affect Moderna Incorporated. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Scope

  • The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Moderna Inc. performance.
  • Moderna is a pipeline biotech company
  • Moderna’s focus is on mRNA-based prophylactic and therapeutic vaccines
  • Moderna’s pipeline is most active in early stages of drug development
  • mRNA-1273 is Moderna’s main weapon against COVID-19

Reasons to Buy

  • An overview of how Moderna Inc. will be affected by the COVID-19 pandemic.

Table of Contents

1. Executive Summary
2. Company Overview
  • Key Stats
  • Sales Forecast Overview

3. Regional Analysis
  • COVID-19 Spread vs. Location of Moderna Inc. Trials
  • COVID-19 vs. Non-COVID-19 Trials

4. Operational Reaction of COVID-19
  • mRNA-1273 Developed Using Proprietary mRNA Technology
  • Insights Exclusive Intel
  • Global Analyst Consensus Sales Forecast
  • Upcoming Events
  • Disrupted Clinical Trials
  • Recent Deal Activity
  • Recruitment Trends

5. Summary
6. Appendix
  • Methodology
  • About the Publisher
  • Contacts